TG Therapeutics Raises 2024 Revenue Guidance Amid Soaring BRIUMVI Sales
TG Therapeutics has reported substantial financial results for the second quarter of 2024, with net sales of their flagship drug BRIUMVI surpassing expectations at $72.6 million. This strong performance has prompted the company to raise its full-year revenue guidance to between $290 million and $300 million. The company also discussed its strategic initiatives, including a partnership with the Department of Veteran Affairs, research and development progress, and plans for a share repurchase program.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
